Search Results

Chris Cargill appointed as President and Chief Executive Officer • Dr.

success Sosei and PharmEnable extend neurological disease drugs hunt Sosei Heptares’ President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma Intelligence Awards Japan 2023 Salipro Biotech

INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease Chris Cargill, President and CEO, will present a company overview at the 41st Annual J.P.

Ep 95 with Chris Langmead Dr. GPCR Podcast << Back to podcast list Chris Langmead Chris Langmead is Professor, Deputy Director, and Prior to joining Heptares, Chris was a neuroscience researcher at GlaxoSmithKline, UK (1998-2009). Chris serves on the editorial boards of the British Journal of Pharmacology, ACS Chemical Neuroscience

Chris Tate Dr. GPCR Podcast << Back to podcast list Dr. Chris Tate About this episode Dr. Chris Tate obtained his Ph.D. from the University of Bristol in 1989 and then moved to the University Chris also worked on the E. coli multidrug transporter EmrE and obtained both 2D and 3D crystals as well Join me to learn more about Chris’s work and his role in founding Heptares which was later acquired by Chris Tate on the web LinkedIn ResearchGate Pubmed Google Scholar Sosei Heptares Wikipedia MRC Laboratory

Chris Evans at UCLA.